| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
Research and development collaborations (note 9) | ||||||||||||
25,888 | 29,544 | 56,592 | 50,786 | 64,904 | 53,019 | 74,165 | 72,230 | 51,572 | 51,762 | 0 | 0 | 0 |
Operating expenses: | ||||||||||||
Research and development | ||||||||||||
0 | - | 84,547 | 69,491 | 0 | - | 55,525 | 52,855 | 45,776 | - | 0 | 0 | 0 |
Government grants and credits | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
Net research and development | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
General and administrative | ||||||||||||
62,797 | 64,177 | 40,233 | 35,507 | 31,394 | 29,457 | 27,876 | 25,720 | 19,357 | 18,550 | 0 | 0 | 0 |
Impairment on acquired IPR&D (note 6) | ||||||||||||
- | - | - | 0 | - | - | - | - | - | 1,536 | 0 | 0 | 0 |
Total operating expenses | ||||||||||||
198,516 | 180,845 | 125,790 | 106,008 | 92,710 | 86,383 | 83,014 | 78,188 | 64,746 | 61,230 | 0 | 0 | 0 |
Loss from operations | ||||||||||||
-172,628 | -151,301 | -69,198 | -55,222 | -27,806 | -33,364 | -8,849 | -5,958 | -13,174 | -9,468 | 0 | 0 | 0 |
Other income (expense): | ||||||||||||
Interest income | ||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - |
Interest and other expense | ||||||||||||
- | - | 103 | 236 | - | - | 193 | 29 | 203 | - | 0 | 0 | 0 |
Change in fair value of warrant liabilities | ||||||||||||
- | - | - | - | - | - | 0 | 3,248 | -553 | - | 0 | 0 | 0 |
Accretion on long-term debt | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
Interest and other income | ||||||||||||
- | - | 5,569 | 4,603 | - | 2,638 | 1,816 | 895 | 951 | 743 | 0 | 0 | 0 |
Other income (expenses), net (note 10) | ||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - |
Foreign exchange (loss) gain | ||||||||||||
- | - | 77 | -119 | - | - | -340 | -154 | -158 | - | 0 | 0 | 0 |
Loss on debt extinguishment | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | - |
Total other income (expense), net | ||||||||||||
9,296 | 5,282 | 5,543 | 4,248 | 1,242 | -1,021 | -2,152 | -2,536 | -2,131 | -494 | 0 | 0 | 0 |
Loss before income taxes | ||||||||||||
-163,332 | -146,019 | -63,655 | -50,974 | -26,564 | -34,385 | -11,001 | -8,494 | -15,305 | -9,962 | 0 | 0 | 0 |
Current income tax recovery (expense) | ||||||||||||
- | - | 359 | 1,237 | - | - | 0 | 0 | 0 | - | 0 | 0 | - |
Deferred income tax recovery | ||||||||||||
- | - | 0 | 0 | - | - | 0 | 0 | 0 | - | 0 | 0 | - |
Income tax expense | ||||||||||||
0 | - | - | - | 0 | - | - | - | - | - | - | - | - |
Net loss and comprehensive loss | ||||||||||||
-162,932 | -145,437 | -63,920 | -52,196 | -28,993 | -36,556 | -13,096 | -10,590 | -15,684 | -10,406 | 0 | 0 | 0 |
Net loss per common share (note 4): | ||||||||||||
Basic and diluted (in dollars per share) | ||||||||||||
-0.64 | - | - | - | -0.43 | - | - | - | - | - | - | - | - |
Basic | ||||||||||||
- | - | -0.70 | -0.89 | - | 0.38 | -0.59 | -0.22 | -0.83 | 1.89 | -0.64 | -0.55 | -1.21 |
Diluted | ||||||||||||
- | - | -0.70 | -0.89 | - | 0.38 | -0.59 | -0.22 | -0.83 | 1.89 | -0.65 | -0.63 | -1.25 |
Weighted-average common shares outstanding (note 4): | ||||||||||||
Basic and diluted (in shares) | ||||||||||||
48,686 | - | - | - | 32,020 | - | - | - | - | - | - | - | - |
Basic | ||||||||||||
- | - | 43,445 | 32,837 | - | 32,071 | 31,959 | 26,869 | 25,459 | 25,558 | 25,339 | 20,915 | 13,183 |
Diluted | ||||||||||||
- | - | 43,445 | 32,837 | - | 32,071 | 31,959 | 26,869 | 25,459 | 25,567 | 25,349 | 21,038 | 13,329 |